176 related articles for article (PubMed ID: 17931087)
41. Polymorphisms in the ABCB1 gene and effect on outcome and toxicity in childhood acute lymphoblastic leukemia.
Gregers J; Gréen H; Christensen IJ; Dalhoff K; Schroeder H; Carlsen N; Rosthoej S; Lausen B; Schmiegelow K; Peterson C
Pharmacogenomics J; 2015 Aug; 15(4):372-9. PubMed ID: 25582575
[TBL] [Abstract][Full Text] [Related]
42. The seventh international childhood acute lymphoblastic leukemia workshop report: Palermo, Italy, January 29--30, 2005.
Aricó M; Baruchel A; Bertrand Y; Biondi A; Conter V; Eden T; Gadner H; Gaynon P; Horibe K; Hunger SP; Janka-Schaub G; Masera G; Nachman J; Pieters R; Schrappe M; Schmiegelow K; Valsecchi MG; Pui CH
Leukemia; 2005 Jul; 19(7):1145-52. PubMed ID: 15902295
[TBL] [Abstract][Full Text] [Related]
43. The impact of CYP3A5*3 on risk and prognosis in childhood acute lymphoblastic leukemia.
Borst L; Wallerek S; Dalhoff K; Rasmussen KK; Wesenberg F; Wehner PS; Schmiegelow K
Eur J Haematol; 2011 Jun; 86(6):477-83. PubMed ID: 21418106
[TBL] [Abstract][Full Text] [Related]
44. Alterations in gamma-actin and tubulin-targeted drug resistance in childhood leukemia.
Verrills NM; Po'uha ST; Liu ML; Liaw TY; Larsen MR; Ivery MT; Marshall GM; Gunning PW; Kavallaris M
J Natl Cancer Inst; 2006 Oct; 98(19):1363-74. PubMed ID: 17018783
[TBL] [Abstract][Full Text] [Related]
45. [Pharmacogenomics of acute lymphoblastic leukemia].
Ansari M; St-Onge G; Krajinovic M
Med Sci (Paris); 2007 Nov; 23(11):961-7. PubMed ID: 18021708
[TBL] [Abstract][Full Text] [Related]
46. Gene polymorphisms in childhood ALL.
Karathanasis NV; Choumerianou DM; Kalmanti M
Pediatr Blood Cancer; 2009 Mar; 52(3):318-23. PubMed ID: 18989891
[TBL] [Abstract][Full Text] [Related]
47. Ponatinib: A new tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia.
Shamroe CL; Comeau JM
Ann Pharmacother; 2013 Nov; 47(11):1540-6. PubMed ID: 24265264
[TBL] [Abstract][Full Text] [Related]
48. Investigation of inherited noncoding genetic variation impacting the pharmacogenomics of childhood acute lymphoblastic leukemia treatment.
Bhattarai KR; Mobley RJ; Barnett KR; Ferguson DC; Hansen BS; Diedrich JD; Bergeron BP; Yoshimura S; Yang W; Crews KR; Manring CS; Jabbour E; Paietta E; Litzow MR; Kornblau SM; Stock W; Inaba H; Jeha S; Pui CH; Cheng C; Pruett-Miller SM; Relling MV; Yang JJ; Evans WE; Savic D
Nat Commun; 2024 May; 15(1):3681. PubMed ID: 38693155
[TBL] [Abstract][Full Text] [Related]
49. Treatment of pediatric acute lymphoblastic leukemia.
Cooper SL; Brown PA
Pediatr Clin North Am; 2015 Feb; 62(1):61-73. PubMed ID: 25435112
[TBL] [Abstract][Full Text] [Related]
50. Resistance revealed in acute lymphoblastic leukemia.
Aster JC; DeAngelo DJ
Nat Med; 2013 Mar; 19(3):264-5. PubMed ID: 23467232
[No Abstract] [Full Text] [Related]
51. Treatment of Relapsed/Refractory Acute Lymphoblastic Leukemia in Adults.
Ronson A; Tvito A; Rowe JM
Curr Oncol Rep; 2016 Jun; 18(6):39. PubMed ID: 27207612
[TBL] [Abstract][Full Text] [Related]
52. Thiopurine S-methyltransferase pharmacogenetics in childhood acute lymphoblastic leukemia.
Yang JJ; Bhojwani D
Methods Mol Biol; 2013; 999():273-84. PubMed ID: 23666706
[TBL] [Abstract][Full Text] [Related]
53. TNF-α SNP rs1800629 and risk of relapse in childhood acute lymphoblastic leukemia: relation to immunophenotype.
Franca R; Rebora P; Athanasakis E; Favretto D; Verzegnassi F; Basso G; Tommasini A; Valsecchi MG; Decorti G; Rabusin M
Pharmacogenomics; 2014 Apr; 15(5):619-27. PubMed ID: 24798719
[TBL] [Abstract][Full Text] [Related]
54. Genetic variants in 6-mercaptopurine pathway as potential factors of hematological toxicity in acute lymphoblastic leukemia patients.
Hareedy MS; El Desoky ES; Woillard JB; Thabet RH; Ali AM; Marquet P; Picard N
Pharmacogenomics; 2015; 16(10):1119-34. PubMed ID: 26237184
[TBL] [Abstract][Full Text] [Related]
55. Pharmacogenomic approaches for tailored anti-leukemic therapy in children.
Stocco G; Franca R; Verzegnassi F; Londero M; Rabusin M; Decorti G
Curr Med Chem; 2013; 20(17):2237-53. PubMed ID: 23458619
[TBL] [Abstract][Full Text] [Related]
56. BCR/ABL1 Kinase Domain Mutation Monitoring: Could Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Benefit As Well?
Andolina JR
Acta Haematol; 2015; 134(2):69-70. PubMed ID: 25895547
[No Abstract] [Full Text] [Related]
57. Treatment of pediatric acute lymphoblastic leukemia.
Tucci F; Aricò M
Haematologica; 2008 Aug; 93(8):1124-8. PubMed ID: 18669975
[No Abstract] [Full Text] [Related]
58. Pharmacogenetics: The right drug for you.
Drew L
Nature; 2016 Sep; 537(7619):S60-2. PubMed ID: 27602742
[No Abstract] [Full Text] [Related]
59. Towards an understanding of the biology and targeted treatment of paediatric relapsed acute lymphoblastic leukaemia.
Irving JA
Br J Haematol; 2016 Mar; 172(5):655-66. PubMed ID: 26568036
[TBL] [Abstract][Full Text] [Related]
60. Biology and treatment of acute lymphoblastic leukemia.
Pieters R; Carroll WL
Pediatr Clin North Am; 2008 Feb; 55(1):1-20, ix. PubMed ID: 18242313
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
